Source: The Business Journals: Washington, D.C.

APT: Md. biotech Adaptive Phage Therapeutics advances fight to wipe out superbugs in cystic fibrosis

The National Institutes of Health is funding its latest clinical trial.

Read full article »
APT's Competitors | APT's News | APT's Financials
Stay up-to-date with the latest news on APT
Est. Annual Revenue
$100K-5.0M
Est. Employees
1-25
Ian Hardy's photo - Interim-CEO of APT

Interim-CEO

Ian Hardy

CEO Approval Rating

- -/100

Read more
Stay up-to-date with the latest news on APT